StockNews.AI
CKPT
StockNews.AI
159 days

SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Investigation into Fairness of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) Buyout Offer and Encourages Investors to Contact the Firm to Discuss Their Legal Rights and Options

1. Kaskela Law is investigating Checkpoint's buyout fairness. 2. Checkpoint agreed to be acquired by Sun Pharmaceutical at $4.10 per share. 3. Analysts believe the buyout undervalues shares priced between $7.00 - $9.00. 4. Shareholders may not receive adequate compensation for their investment. 5. The acquisition will remove Checkpoint from public trading.

4m saved
Insight
Article

FAQ

Why Bearish?

The investigation into the fairness of the buyout adds uncertainty. Historical precedence shows significant volatility in similar cases, often leading to price corrections as seen in other M&A deals like Celgene's acquisition of Juno Therapeutics, which faced similar scrutiny.

How important is it?

The investigation indicates potential legal risks and shareholder concerns that affect confidence.

Why Short Term?

Investor sentiment may shift quickly due to ongoing legal scrutiny. The initial impact can often be felt in days to weeks as shareholders react.

Related Companies

SNPSCELGJNJ
PHILADELPHIA, March 13, 2025 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating the fairness of the recently announced buyout of Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT) shareholders. Click here for additional information: https://kaskelalaw.com/case/checkpoint/ On March 9, 2025, Checkpoint announced that it had agreed to be acquired by Sun Pharmaceutical Industries Ltd. at an upfront price of $4.10 per share in cash plus a non-transferable contingent value right (CVR) worth up to an additional $0.70 in cash upon the achievement of certain milestones. Following the closing of the proposed transaction, Checkpoint’s shareholders will be cashed out of their investment position and the company’s shares will no longer be publicly traded. The investigation seeks to determine whether Checkpoint’s shareholders will be receiving sufficient monetary consideration for their shares, and whether the company’s officers and/or directors breached their fiduciary duties or violated the securities laws in agreeing to the buyout price. Notably, at the time the proposed transaction was announced, several stock analysts were maintaining price targets for the company’s shares well above the buyout price at between $7.00 - $9.00 per share. Checkpoint shareholders are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq. or Adrienne Bell, Esq.) at (484) 229 – 0750 for additional information about this investigation and their legal rights and options. Alternatively, investors may submit their information to the firm by clicking on the following link (or if necessary, by copying and pasting the link into your browser): https://kaskelalaw.com/case/checkpoint/ Kaskela Law LLC exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis, which means that the firm’s clients never pay any out-of-pocket costs for legal representation. For additional information about Kaskela Law LLC, including the firm’s recent notable recoveries for investors, please visit www.kaskelalaw.com. CONTACT: KASKELA LAW LLC D. Seamus Kaskela, Esq.(skaskela@kaskelalaw.com)Adrienne Bell, Esq.(abell@kaskelalaw.com)18 Campus Blvd., Suite 100Newtown Square, PA 19073(484) 229 – 0750www.kaskelalaw.com This notice may constitute attorney advertising in certain jurisdictions.

Related News